Two studies have assessed whether chronic INL insulin administration modified AD biomarkers, with one showing null findings [212] and the other suggesting that the intervention modified CSF tau-P181/Aβ42 ratio [273]. This evidence concerns the gene MAPT and Alzheimer disease.